Zentalis Pharmaceuticals ( (ZNTL) ) has issued an announcement.
Zentalis Pharmaceuticals presented updated clinical data at the Society of Gynecologic Oncology 2025 Annual Meeting, highlighting the potential of azenosertib in treating platinum-resistant ovarian cancer (PROC). The data from the DENALI Part 1b clinical trial showed a median duration of response of 6.3 months and an objective response rate of approximately 35% in response-evaluable patients. The company plans to initiate Part 2 of the trial in the first half of 2025, with topline data expected by the end of 2026, potentially supporting accelerated approval. The presentation also emphasized the role of Cyclin E1 protein overexpression as a predictive biomarker for identifying patients who could benefit from azenosertib.
More about Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing azenosertib, a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). The company is evaluating azenosertib as both a monotherapy and in combination across multiple tumor types in clinical trials, with operations based in San Diego.
YTD Price Performance: -41.00%
Average Trading Volume: 1,863,071
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $126.1M
For an in-depth examination of ZNTL stock, go to TipRanks’ Stock Analysis page.